Other

Surmodics, Inc.

Evonik Corporation

Evonik Operations Gmbh

Evonik Roehm Gmbh

Edge Therapeutics, Inc.

Surmodics Pharmaceuticals, Inc.

Genzyme Corporation

Kevin Burton

Thomas R Tice

Arthur J Tipton

Norbert Windhab

R Loch Macdonald

Gary Anthony Winchester

Cara R Davis

Angela R Stella

Thomas C Bischoff

Nathan Lockwood

Aleksey V Kurdyumov

Joseph Schmidt McGonigle

Andreas Karau

Jeffrey Missling

Andrea Engel

Julia Lyubina

Peter Niepoth

William Ferris

Christoph Brücher

Paul Joseph Spencer

Parissa Heshmati

Rima Jaber

Axel Schroeder

Tom Tice

Jessica Müller-Albers

Beth A Petersen

Torsten Woehr

Mimoun Ayoub

Carsten Dentler

Rüdiger Alexowsky

Axel SCHRÖDER

A method of unambiguous identification and authentication of products for the purpose of better recognition of product forgeries and controlling product piracy, including applying to/into the product an identification substance admixture which contains paramagnetic phases or identifying a product which contains an identification substance admixture containing paramagnetic phases and has an ESR fingerprint spectrum that permits unambiguous identification of the product. Such an ESR fingerprint spectrum is easily measurable, but can be copied or forged only with difficulty. The method relates to an individualizable 'femto tag' for femto ledgers and forms an important interface for what are known as “Internet of Things” (IOT).

Unique identification and authentication of products

An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

A biocompatible polymeric controlled release matrix barrier structure for delivery of one or more bioactive agents from an implantable medical device is described. In an embodiment, a biocompatible polymeric controlled release matrix barrier structure is included. The biocompatible polymeric controlled release matrix can include a body structure formed of a compliant material comprising one or more compliant biocompatible polymers and one or more bioactive agents. The body structure can define a central aperture through which a subcutaneous element of an implantable medical device passes. Other embodiments are included herein.

Controlled release matrix barrier structure for subcutaneous medical devices

Disclosed herein are compositions comprising cross-linkers for cross-linking a retention vehicle polymer. The compositions are particularly useful for local administration of a bioactive agent, wherein prolonged or extended availability of the bioactive agent at the site of administration is desired. Also disclosed are methods of delivering the compositions to a subject.

Compositions and methods for improved retention of a pharmaceutical composition at a local administration site

Described herein are implantable composites, articles comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.

Implantable composites and implants comprising same

The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Polymorph compositions, methods of making, and uses thereof

Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods.

Elastic implantable composites and implants comprising same

Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Controlled-released peptide formulations

Growing community of inventors

Hoover, AL, United States of America

Kevin Burton